Evaluation of short-and long-term response to treatment in GIMEMA protocol for acute myeloid leukaemia

I. Ardoino; F. Ambrogi; S. Iacobelli; P. Boracchi; G. Manikis; M. G. Kounelakis; M. Zervakis; P. J G Lisboa; P. Fazi; M. Vignetti; E. M. Biganzoli; A. Starita

doi:10.1504/IJBET.2010.032699

Evaluation of short-and long-term response to treatment in GIMEMA protocol for acute myeloid leukaemia

I. Ardoino, F. Ambrogi, S. Iacobelli, P. Boracchi, G. Manikis, M. G. Kounelakis, M. Zervakis, P. J G Lisboa, P. Fazi, M. Vignetti, E. M. Biganzoli, A. Starita

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article

Abstract

Acute Myeloid Leukaemia (AML) is a haematologic malignancy. Despite of improvements in prognosis it is still a severe disease and only a minority of patients are cured. Recently, insights into specific cytogenetics and biological aberration involved in the leukaemogenesis process are the target of research. LAM-99P GIMEMA Protocol identifies treatment guidelines for AML in adults. A methodological approach is proposed, compounding different modelling techniques, to assess the prognostic relevance of clinical as well as biological markers with regard to clinical endpoint, such as the achievement of Complete Remission in the short-term and long-term survival taking into account competing risks.

Original language	English
Pages (from-to)	329-348
Number of pages	20
Journal	International Journal of Biomedical Engineering and Technology
Volume	3
Issue number	3-4
DOIs	https://doi.org/10.1504/IJBET.2010.032699
Publication status	Published - Apr 2010

Keywords

Acute myeloid leukaemia
AML
Competing risks
CR
Multinomial logistic regression
Support vector machines
Survival analysis

ASJC Scopus subject areas

Biomedical Engineering

Access to Document

10.1504/IJBET.2010.032699

Fingerprint Dive into the research topics of 'Evaluation of short-and long-term response to treatment in GIMEMA protocol for acute myeloid leukaemia'. Together they form a unique fingerprint.

Cite this

Ardoino, I., Ambrogi, F., Iacobelli, S., Boracchi, P., Manikis, G., Kounelakis, M. G., Zervakis, M., Lisboa, P. J. G., Fazi, P., Vignetti, M., Biganzoli, E. M., & Starita, A. (2010). Evaluation of short-and long-term response to treatment in GIMEMA protocol for acute myeloid leukaemia. International Journal of Biomedical Engineering and Technology, 3(3-4), 329-348. https://doi.org/10.1504/IJBET.2010.032699

Evaluation of short-and long-term response to treatment in GIMEMA protocol for acute myeloid leukaemia. / Ardoino, I.; Ambrogi, F.; Iacobelli, S.; Boracchi, P.; Manikis, G.; Kounelakis, M. G.; Zervakis, M.; Lisboa, P. J G; Fazi, P.; Vignetti, M.; Biganzoli, E. M.; Starita, A.

In: International Journal of Biomedical Engineering and Technology, Vol. 3, No. 3-4, 04.2010, p. 329-348.

Research output: Contribution to journal › Article

Ardoino, I, Ambrogi, F, Iacobelli, S, Boracchi, P, Manikis, G, Kounelakis, MG, Zervakis, M, Lisboa, PJG, Fazi, P, Vignetti, M, Biganzoli, EM & Starita, A 2010, 'Evaluation of short-and long-term response to treatment in GIMEMA protocol for acute myeloid leukaemia', International Journal of Biomedical Engineering and Technology, vol. 3, no. 3-4, pp. 329-348. https://doi.org/10.1504/IJBET.2010.032699

Ardoino, I. ; Ambrogi, F. ; Iacobelli, S. ; Boracchi, P. ; Manikis, G. ; Kounelakis, M. G. ; Zervakis, M. ; Lisboa, P. J G ; Fazi, P. ; Vignetti, M. ; Biganzoli, E. M. ; Starita, A. / Evaluation of short-and long-term response to treatment in GIMEMA protocol for acute myeloid leukaemia. In: International Journal of Biomedical Engineering and Technology. 2010 ; Vol. 3, No. 3-4. pp. 329-348.

@article{98787bb0e3d44dcebb16234ed54b200f,

title = "Evaluation of short-and long-term response to treatment in GIMEMA protocol for acute myeloid leukaemia",

abstract = "Acute Myeloid Leukaemia (AML) is a haematologic malignancy. Despite of improvements in prognosis it is still a severe disease and only a minority of patients are cured. Recently, insights into specific cytogenetics and biological aberration involved in the leukaemogenesis process are the target of research. LAM-99P GIMEMA Protocol identifies treatment guidelines for AML in adults. A methodological approach is proposed, compounding different modelling techniques, to assess the prognostic relevance of clinical as well as biological markers with regard to clinical endpoint, such as the achievement of Complete Remission in the short-term and long-term survival taking into account competing risks.",

keywords = "Acute myeloid leukaemia, AML, Competing risks, CR, Multinomial logistic regression, Support vector machines, Survival analysis",

author = "I. Ardoino and F. Ambrogi and S. Iacobelli and P. Boracchi and G. Manikis and Kounelakis, {M. G.} and M. Zervakis and Lisboa, {P. J G} and P. Fazi and M. Vignetti and Biganzoli, {E. M.} and A. Starita",

year = "2010",

month = apr,

doi = "10.1504/IJBET.2010.032699",

language = "English",

volume = "3",

pages = "329--348",

journal = "International Journal of Biomedical Engineering and Technology",

issn = "1752-6418",

publisher = "Inderscience Enterprises Ltd",

number = "3-4",

}

TY - JOUR

T1 - Evaluation of short-and long-term response to treatment in GIMEMA protocol for acute myeloid leukaemia

AU - Ardoino, I.

AU - Ambrogi, F.

AU - Iacobelli, S.

AU - Boracchi, P.

AU - Manikis, G.

AU - Kounelakis, M. G.

AU - Zervakis, M.

AU - Lisboa, P. J G

AU - Fazi, P.

AU - Vignetti, M.

AU - Biganzoli, E. M.

AU - Starita, A.

PY - 2010/4

Y1 - 2010/4

N2 - Acute Myeloid Leukaemia (AML) is a haematologic malignancy. Despite of improvements in prognosis it is still a severe disease and only a minority of patients are cured. Recently, insights into specific cytogenetics and biological aberration involved in the leukaemogenesis process are the target of research. LAM-99P GIMEMA Protocol identifies treatment guidelines for AML in adults. A methodological approach is proposed, compounding different modelling techniques, to assess the prognostic relevance of clinical as well as biological markers with regard to clinical endpoint, such as the achievement of Complete Remission in the short-term and long-term survival taking into account competing risks.

AB - Acute Myeloid Leukaemia (AML) is a haematologic malignancy. Despite of improvements in prognosis it is still a severe disease and only a minority of patients are cured. Recently, insights into specific cytogenetics and biological aberration involved in the leukaemogenesis process are the target of research. LAM-99P GIMEMA Protocol identifies treatment guidelines for AML in adults. A methodological approach is proposed, compounding different modelling techniques, to assess the prognostic relevance of clinical as well as biological markers with regard to clinical endpoint, such as the achievement of Complete Remission in the short-term and long-term survival taking into account competing risks.

KW - Acute myeloid leukaemia

KW - AML

KW - Competing risks

KW - CR

KW - Multinomial logistic regression

KW - Support vector machines

KW - Survival analysis

UR - http://www.scopus.com/inward/record.url?scp=78651576672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651576672&partnerID=8YFLogxK

U2 - 10.1504/IJBET.2010.032699

DO - 10.1504/IJBET.2010.032699

M3 - Article

AN - SCOPUS:78651576672

VL - 3

SP - 329

EP - 348

JO - International Journal of Biomedical Engineering and Technology

JF - International Journal of Biomedical Engineering and Technology

SN - 1752-6418

IS - 3-4

ER -